

News Release

October 6, 2005

Flu-X – a newly developed anti-flu medicine launched today by Sino Pharmaceuticals Corporation in response to growing concern over a major flu epidemic in North America and the concomitant shortage of flu vaccines.

Flu-X kills the Influenza A & B viruses upon contact*.

Sino Pharmaceuticals Corporation today launched Flu-X – a new anti-flu medicine that kills the Influenza A & B viruses upon contact.

Sino Pharmaceuticals Corporation CEO and President, Moe Aziz, says “We are pleased to introduce our newly developed anti-flu medicine, *Flu-X*[™] in response to the growing concern over a major flu epidemic in North America. The result of over three years of scientific and clinical research & development, *Flu-X* is a highly effective, non-prescription, over-the-counter (OTC), oral anti-flu spray and is a patented scientific formulation of five standardized Chinese herb extracts, which has been clinically demonstrated, in several scientific studies and animal and human patient trials, to kill both Influenza A & B viruses upon contact, thus preventing contraction of the flu. These studies and trials also confirm that *Flu-X* prevents the replication of both Influenza A & B viruses, thereby preventing and reducing the severity of the flu and common cold. The product has been used by over 1,000 patients and has been shown to be highly effective in the prevention and treatment of influenza and the common cold.”

Flu-X was originally developed by Professor D.S. Liu, one of China’s most eminent and respectable virologists and medical doctors, as an anti-SARS virus drug during China’s SARS epidemic in 2003 and was successfully used to treat SARS-infected patients at several hospitals in China.

Professor D. S. Liu has over 40 years experience in molecular biology and virology and graduated as a physician from China’s prestigious China Medical University. He completed his post-graduate degree at the China Academy of Medical Sciences under the supervision of Professor Zhu Jiming, the scientist who isolated the first Asian influenza strain in the world, in the 1950’s. Professor Liu has worked extensively as a virologist with projects with the World Health Organization (WHO), Royal Post Graduate Medical School, U.K. and Wellcome Research Laboratories in the U.K. He was awarded the “National Special Contribution Scientist Award” by the State Council of China and is a member of the editorial committee of “China Biological Products Journal” and “China Immunology Journal”. He is also scientific advisor for anti-cancer drug development at Swiss Debiopharm Research Foundation.

ABOUT SINO PHARMACEUTICALS CORPORATION

Sino Pharmaceuticals Corporation is an innovative, specialty pharmaceuticals company, based in Vancouver, Canada, dedicated to the development, manufacturing and marketing of generic pharmaceuticals as well as the research, development and discovery of new ethical drugs in the cardiovascular, cancer and anti-viral therapeutic areas. The company has operations in Canada, China and the U.S.

CONTACT:

Moe S. Aziz
President & CEO
Sino Pharmaceuticals Corporation
Telephone: 1 (604) 303-9180
Fax: 1 (604) 303-9170
E-mail: maziz@sinopharmaceuticals.com

Website: <http://www.flu-x.com>
<http://www.sinopharmaceuticals.com>

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. This news release contains forward-looking statements, including statements regarding the development of Flu-X, results from the Flu-X clinical trials, that involve risks and uncertainties and are subject to change. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements often address our expected future performance and often contain words such as "expects," "anticipates," "intends," "plans," "believes," "seeks" or "will." Such risks and uncertainties include, but are not limited to, completion of clinical trials, patient enrolment rates, uncertainty of pre-clinical, retrospective and early clinical trial results, and market acceptance of the Company's products.